Skip to content
Open access

Dendritic-cell-targeting adeno-associated virus as potent cancer vaccine carriers

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 40 references
Medicine

TL;DR

This study establishes this engineered AAV as a versatile and potent vaccine platform that effectively targets DCs, offering a promising approach for inducing robust and adaptable anti-tumor immunity.

Abstract

Background The clinical efficacy of therapeutic cancer vaccines is critically limited by the inefficient in vivo delivery of tumor antigens to dendritic cells (DCs), the key regulators of T-cell immunity. Methods To address this issue, we developed a dendritic-cell-targeting adeno-associated virus (AAV) vector through rational capsid design. This was achieved by site-specifically inserting the high-affinity Clec9a-targeting peptide CBP-12, optimizing its flanking sequences, and introducing T491V/S662V gain-of-function mutations to synergistically enhance DC transduction. Results The resulting vector, AAV2-mut-Peptide2, showed significantly improved tropism for and gene delivery efficiency to cross-presenting cDC1s in vivo. In murine models of hepatocellular carcinoma, vaccination with this platform, encoding either a model antigen (OVA) or the endogenous tumor-associated antigen GPC3, elicited a potent antigen-specific CD8+ T cell response. This response was characterized by a substantial increase in tumor-infiltrating lymphocytes, enhanced production of key effector cytokines, and consequently, potent suppression of tumor growth. Conclusion Our study establishes this engineered AAV as a versatile and potent vaccine platform that effectively targets DCs, offering a promising approach for inducing robust and adaptable anti-tumor immunity.

Read PDF

Similar papers

Nov 2026

Adenovirus-Derived Virus-Like Particles Enable Rapid Encapsulation and Delivery of Functional Antigen Cargo

Adenoviral vectors have been widely validated as effective vaccine platforms for both infectious diseases and cancer due to their strong immunostimulatory properties. However, their application to personalized cancer vaccines and other time-sensitive antigens is limited by the prolonged production time required for c...

Jia-Bao Han, E. Kashentseva, Igor P. Dmitriev et al. · 0 citations
#protein folding Open access Nov 2026

CD3scFv-Engineered AAV Capsid Drives Superior In Vitro and In Vivo CAR-T Cell Generation and Leads to Complete Eradication of CD19+ Tumors.

It is demonstrated that site-selective CD3scFv insertion into a single AAV capsid protein provides a robust, versatile platform for improved T cell transduction and effective in vivo CAR-T cell generation, offering a promising off-the-shelf approach for treating B cell malignancies.

Hai-Feng Chen, T. Hoang, A. Smith et al. · 0 citations
Review Open access Oct 2026

Targeting Dendritic Cells in Cancer Immunotherapy: From Immune Priming to Tumor Microenvironment Reprogramming.

The biological rationale for DC-directed immunotherapy, tumor-induced DC dysfunction, next-generation DC platforms, in vivo DC targeting, DC-derived extracellular vesicles, negative and controversial clinical evidence, and rational combinations with checkpoint blockade and tumor-microenvironment-modulating strategies a...

Serena Zanotta, Domenico Galati · 0 citations
Review Open access Nov 2026

Engineered Allogeneic Dendritic Cell Vaccines: Coordinating Antitumor Immunity and Advancing Translation in Pancreatic Cancer

Dendritic cells (DCs) coordinate antigen presentation and immune-effector activation, but vaccine-induced immune responses have not consistently translated into clinical benefit. This focused narrative review evaluates therapeutic vaccination in established pancreatic cancer and potential adjuvant use after resection,...

Kawaljit Kaur · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.